## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -6.4% below STRENGTH zone (4.0-10.0%); PEG 1.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($334.47)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Should Stryker’s (SYK) New Internal Leadership Team Redefine Expectations Around Execution And Innovation?**
- Source: Simply Wall Street | 20251209T062138 | Somewhat-Bullish | Relevance: 99%
-  Stryker Corporation has announced key leadership changes, with Spencer Stiles becoming President and COO, and Dylan Crotty promoted to Group President of Orthopaedics, effective January 1, 2026. These internal promotions emphasize continuity and succession planning, which will influence the company's growth, innovation, and global expansion strategies. Investors should consider how this leadership team will sustain Stryker's growth profile amidst rising R&D and compliance costs, particularly in light of the company's upsized 2025 organic net sales growth outlook.

**2. Natixis Has $35.77 Million Position in Stryker Corporation $SYK**
- Source: MarketBeat | 20251208T122742 | Somewhat-Bullish | Relevance: 99%
-  Natixis significantly increased its stake in Stryker Corporation, boosting its holdings by 50.5% to 90,408 shares valued at $35.77 million. This comes as Stryker reported strong quarterly results with better-than-expected EPS and revenue, setting a positive outlook for FY2025. Despite substantial insider selling in the last 90 days, institutional ownership remains high at 77.1%, and analysts maintain a "Moderate Buy" rating for the medical technology company.

**3. Axa S.A. Purchases 43,333 Shares of Stryker Corporation $SYK**
- Source: MarketBeat | 20251209T090921 | Somewhat-Bullish | Relevance: 99%
- Axa S.A. increased its stake in Stryker Corporation by 33.2% in the second quarter, acquiring an additional 43,333 shares, bringing its total holdings to 173,884 shares valued at $68.79 million. Other institutional investors like Norges Bank and Price T Rowe Associates Inc. MD also significantly increased their positions in the medical technology company. Stryker's stock recently traded down 3%, with analysts giving it a "Moderate Buy" consensus rating and a target price of $433.78.

**4. State Street Corp Increases Stake in Stryker Corporation $SYK**
- Source: MarketBeat | 20251209T134902 | Somewhat-Bullish | Relevance: 98%
-  State Street Corp increased its stake in Stryker Corporation (NYSE:SYK) by 1.0% during the second quarter, now owning 3.91% of the company's stock valued at over $5.9 billion. Other institutional investors have also adjusted their positions, and analysts generally rate Stryker as a "Moderate Buy" with an average target price of $433.78. Recent insider transactions show executives selling shares.

**5. Does Stryker’s Premium Valuation Still Make Sense After Recent Share Price Volatility?**
- Source: Simply Wall Street | 20251207T070919 | Neutral | Relevance: 98%
- Stryker's stock has experienced recent volatility but has shown strong longer-term returns, driven by its medical technology portfolio. Despite its strong performance, Simply Wall St's valuation checks, including Discounted Cash Flow and Price to Earnings ratio, suggest that the stock may be overvalued. The article introduces "Narratives" as a way for investors to connect their view of Stryker's business to its fair value.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-14 | Truist Securiti | $400 | $392 | +2% |
| 2025-11-14 | Wells Fargo | $456 | $452 | +1% |
| 2025-11-14 | Needham | $448 | $448 | 0% |
| 2025-11-14 | BTIG | $410 | $410 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-14 | Truist Securiti | main | Hold |
| 2025-11-14 | Wells Fargo | main | Overweight |
| 2025-11-14 | Needham | reit | Buy |
| 2025-11-14 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($34.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.9% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $35M sold (6 transactions in 90 days).
3. Long-term trend broken: trading 7.3% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.86 elevated, pricing in significant growth expectations. Forward P/E 23.4x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($34.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $133.6B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.86 |
| Forward P/E | 23.4 |
| Current P/E | 25.8 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.6% to -6.4% (-4.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 10.4pp (needs >4.0% for momentum thesis). AM_20 at -4.4% indicates price below own 20MA trend. Below SMA200 (0.93x), long-term trend not supportive. MACD histogram bearish (-1.52), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -6.44% (CS: 8) | Weak |
| RSI_14 | 34.3 | Neutral |
| MACD Histogram | -1.52 | Bearish |
| vs SMA20 | 0.956x | Below |
| vs SMA50 | 0.950x | Below |
| vs SMA200 | 0.927x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $349.23
- **Stop Loss:** $334.47 (4.2% risk)
- **Target:** $363.99 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 20
- **Position Value:** $6,984.60
- **Portfolio %:** 6.98%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*